SCHEDULE 13D/A: OrbiMed Reduces Stake in Compass Therapeutics, Sells Over 7 Million Shares
Beneficial Ownership Update
OrbiMed Advisors and affiliated entities have significantly reduced their beneficial ownership in Compass Therapeutics, Inc. by selling over 7 million shares, though they retain an 11.0% stake.
Summary
- OrbiMed Advisors LLC and its affiliated reporting persons (OrbiMed Capital GP V LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital LLC) filed Amendment No. 5 to their Schedule 13D regarding Compass Therapeutics, Inc.
- The filing reports a decrease of more than 1% in the beneficial ownership of outstanding shares held by the Reporting Persons.
- Following the transactions, OrbiMed Genesis GP LLC and OrbiMed Capital LLC ceased to be beneficial owners of Compass Therapeutics shares.
- On April 9, 2025, OrbiMed Genesis Master Fund, L.P. sold 3,571,428 shares at a price of $1.59 per share.
- On April 9, 2025, The Biotech Growth Trust PLC (BIOG) sold 3,571,428 shares at a price of $1.59 per share.
- As of the filing date, OrbiMed Private Investments V KA, LP (OPI V-KA) holds 15,219,994 shares, representing approximately 11.0% of the 138,282,498 outstanding shares of Compass Therapeutics, Inc.
Sentiment
Score: 3
Explanation: The sentiment is negative due to a significant reduction in beneficial ownership by a major institutional investor, which can be interpreted as a decrease in confidence or a strategic divestment.
Positives
- Despite the reduction, OrbiMed Advisors and its remaining affiliated entities still maintain a significant 11.0% beneficial ownership stake in Compass Therapeutics, indicating continued, albeit reduced, investment interest from a major biotech investor.
Negatives
- Two OrbiMed-affiliated entities, OrbiMed Genesis Master Fund, L.P. and The Biotech Growth Trust PLC (BIOG), completely divested their holdings in Compass Therapeutics, selling a combined 7,142,856 shares.
- The sale of a substantial number of shares by a major institutional investor could signal a reduction in confidence or a strategic portfolio rebalancing, potentially impacting market perception.
Risks
- The Reporting Persons stated their intent to review their investment in the Issuer based on various factors and may determine to dispose of some or all of their currently owned shares in the future, either in the open market or in privately negotiated transactions, which could exert downward pressure on the stock price.
Future Outlook
The Reporting Persons intend to periodically review their investment in Compass Therapeutics based on various factors, including the Issuer's business, financial condition, market conditions, and other investment opportunities. They may acquire additional shares or dispose of existing shares in the future depending on these factors.
Industry Context
This filing reflects a change in a significant institutional investor's position within a biotechnology company. While specific industry trends are not detailed, such adjustments by major biotech-focused funds like OrbiMed can be indicative of portfolio rebalancing or evolving views on specific companies within the sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Standing Arrangement | Carl L. Gordon, a member of OrbiMed Advisors and a director of Compass Therapeutics, is obligated to transfer any equity-based compensation received from the Issuer to OrbiMed Advisors and OrbiMed GP, which will then ensure such benefits are provided to OPI V-KA. | N/A | This arrangement ensures that equity compensation received by the OrbiMed-affiliated director benefits the OrbiMed fund, aligning the director's incentives with the fund's investment in the Issuer. |
Related Party Transactions
- Carl L. Gordon, a director of Compass Therapeutics and a member of OrbiMed Advisors, has an agreement to transfer any stock options or equity-based compensation received from Compass Therapeutics to OrbiMed Advisors and OrbiMed GP, which will then provide them to OPI V-KA.
Stakeholder Impact
- Shareholders: The reduction in stake by a major institutional investor could lead to negative market sentiment and potential downward pressure on the share price.
- Employees, Customers, Suppliers, Creditors: No direct impact mentioned in this filing, as it pertains solely to investor ownership changes.
Next Steps
- OrbiMed Reporting Persons will continue to review their investment in Compass Therapeutics and may take further actions, including acquiring or disposing of shares, based on their ongoing assessment of the Issuer and market conditions.
Key Dates
| Date | Description |
|---|---|
| 2020-06-29 | Original Statement on Schedule 13D filed by OrbiMed Reporting Persons. |
| 2021-07-14 | Amendment No. 1 to Schedule 13D filed. |
| 2021-11-09 | Amendment No. 2 to Schedule 13D filed. |
| 2022-11-10 | Amendment No. 3 to Schedule 13D filed. |
| 2024-03-22 | Amendment No. 4 to Schedule 13D filed. |
| 2025-02-27 | Compass Therapeutics, Inc.'s Annual Report on Form 10-K filed with the SEC, stating 138,282,498 outstanding shares. |
| 2025-04-09 | Date of event requiring filing; Genesis Master Fund and BIOG sold shares at $1.59 per share. |
| 2025-04-11 | Date of execution of the Joint Filing Agreement and signature date for Amendment No. 5. |
Keywords
Compass Therapeutics, OrbiMed Advisors, Schedule 13D/A, Beneficial Ownership, Biotech, Investment Fund, Share Sale, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.